LEXICON PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Current
LEXICON PHARMACEUTICALS, INC. (LXRX) had Debt Securities, Available-for-sale, Current of $149.69 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Current $149.69M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $132.57M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $61.90M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $66.29M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $149.69M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $132.57M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $61.90M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $66.29M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $117.64M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $131.95M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $171.30M 10-K · filed 2026-03-05 |
| 2024-09-30 | $223.82M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $274.35M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $259.10M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $147.56M 10-K · filed 2025-03-07 |
| 2023-09-30 | $197.31M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $154.47M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $79.94M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $92.01M 10-K · filed 2024-03-25 |
| 2022-09-30 | $117.37M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $40.52M 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |